Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Celan Biology: No research on HIV vaccine has been conducted.
06/08/2025
Celan Biotech stated on the interactive platform that the company has not conducted any research related to an AIDS vaccine.
Latest
1 m ago
Three departments: By 2027, the rate of bus service accessibility in rural villages should reach 55% or above.
1 m ago
YiYuan Communication: The module has been deeply applied in the field of financial payments, including scenarios for digital currency payments.
2 m ago
Po Sang (02378.HK) spent 3.033 million pounds on August 5 to repurchase 318,300 shares.
3 m ago
Market news: It is reported that iQIYI is seeking to raise $300 million through listing on the Hong Kong market.
3 m ago
Thomson Reuters Corporation's second-quarter revenue increased by 5% on a fixed exchange rate basis. The company expects the adjusted EBITDA margin for the third quarter of 2025 to be around 36%.
See all latest